Mercadon locks out TRACEr technology to develop next-generation T-cell therapy

Blinatumomab, approved in China on December 8th for the treatment of patients with relapsed or refractic B-cell precursor acute lymphoblastic leukemia (ALL), is a TCE therapy.
, Belintoo monoantin is still the only TCE approved.
effective dose of TCE is more than 10,000 times lower than that of typical antibodies, but TCE also has limitations such as dose-limiting toxicity, poor pharmacodynamic properties, and reduced efficacy.
, systemic immunoactivation is a major obstacle to the development of TCE therapy.
The first generation of TCE triggers a systemic immune response that attacks not only tumors, but also healthy tissue, and the toxicity that can be life-threatening;
not only limits the development of TCE, but also reduces the dose of drugs that can be used safely.
In response to these limitations, Janux developed tumor-activated T Cell Connecter (Tumored T Cell Engager, TRACTr) technology that, by combining cross-pharmacological dynamics with tumor-specific activation, enables the drug to actively accumulate in tumors and prevents the drug from accumulating in healthy tissue.
preclinical studies have shown that TRACTr drugs can achieve high safety multiples and have anti-tumor properties comparable to standard TCE, while preventing cytokine release, healthy tissue toxicity, and systemic immunoactivation.
source: Janux's official website TCE is highly effective in blood cancers, and although TCE for solid tumors is not currently approved, about one-third of ongoing clinical trials worldwide are targeted at solid tumors, similar to car-T ratios.
Janux pipeline also has a number of drugs being developed that target solid tumors, including colorectal, gastroesophageal, prostate, non-small cell lung, triple-negative breast and ovarian cancer.
" partnership with Mercator provides us with important expertise and resources to develop the next generation of T-cell bridger therapies, which are expected to enable immunotherapy to serve more cancer patients.
," said Dr. David Campbell, President and CEO of Janux.
。